Vectura subsidiary Jagotec has entered into a development and license deal with Sandoz for its VR2081 combination therapy MDI for the treatment of asthma and COP, the company announced. Sandoz will pay $5 million up front and up to an additional $5 million in milestone payments, plus royalties on net sales, for US rights to the product.
According to Vectura, regulatory submission and launch of the inhaler, if approved, is expected in “the early to mid-2020’s.” Sandoz will be responsible for clinical development, manufacturing, and commercialization.
Vectura CEO James Ward-Lilley said, “This agreement, extending our existing strong relationship with Sandoz, further reinforces Vectura’s compelling position as a leader in the development of inhaled novel and generic products leveraging our suite of formulation and device platforms and proven development capabilities. Following the merger of Vectura and Skyepharma last summer we announced that we were prioritizing three to five generic projects utilizing the group’s newly combined pMDI and DPI device platforms. This program represents the first partnered collaboration of this series of projects and offers substantial potential for future value creation.”
Read the Vectura press release.
